HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women [3]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 1090-1092

  Vogelvang, T E ^a   Leurs, J R ^b   Mijatovic, V ^a   Willemse, J ^b   Van Der Mooren, M J ^b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; C REACTIVE PROTEIN; DYDROGESTERONE; ESTRADIOL; ESTROGEN RECEPTOR; HMR 3339; LYSINE; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRIMEGESTONE; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ANGINA PECTORIS; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; FIBRINOLYSIS; HORMONAL THERAPY; HUMAN; LETTER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VEIN THROMBOSIS; BIOSYNTHESIS; FEMALE; METABOLISM; MULTICENTER STUDY; POSTMENOPAUSE; RISK; TIME;

CARBOXYPEPTIDASE U; ESTRADIOL; FEMALE; FIBRINOLYSIS; HUMANS; MULTICENTER STUDIES; ODDS RATIO; PLACEBOS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 23844460305     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01306.x     Document Type: Letter

References (13)

1. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
2. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
3. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vase Biol 2000; 20: 2156-61.
4. Walsh BW, Kuller LH, Wild RA, Paul S, Fanner M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51.
5. Vogelvang TE, Leurs JR, van der Mooren MJ, Mijatovic V, Hendriks DF, Neele SJM, Netelenbos JC, Kenemans P. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women. Menopause 2004; 11: 110-5.
6. Vogelvang TE, Mijatovic V, Kenemans P, Teerlink T, van der Mooren MJ. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertil Steril 2004; 82: 1540-9.
7. Vogelvang TE, Mijatovic V, Kenemans P, Schalkwijk CG, van der Mooren MJ. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women. Am J Cardiol 2004; 94: 1205-8.
8. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women, four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57.
9. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women-results from the MORE randomized trial. JAMA 1999; 281: 2189-97.
10. Schatteman KA, Goossens FJ, Leurs JR, Kasahara Y, Scharpe SS, Hendriks DF. Fast homogeneous assay for plasma procarboxypeptidase U. Clin Chem Lab Med 2001; 39: 806-10.
11. Post MS, Hendriks DF, van der Mooren MJ, van Baal WM, Leurs JR, Emeis JJ, Kenemans P, Stehouwer CDA. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized placebo-controlled 12-week study in early postmenopausal women. J Intern Med 2002; 251: 245-51.
12. Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003; 1: 1208-14.
13. Gils A, Alessi MC, Brouwers E, Peelers M, Marx P, Leurs JR, Bouma B, Hendriks DF, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vase Biol 2003; 23: 1122-7.